Press Releases

61_IGC-Pharma-Announces-New-Preclinical-Data-Demonstrating-TGR-63’s (1)
IGC Pharma Announces Preclinical Data Demonstrating TGR-63’s Dual Action on Alzheimer’s Pathology 
Read More →
61_IGC-Pharma-Achieves-50-Patient-Enrollment-Milestone
IGC Pharma Reports 50% Patient Enrollment Milestone in Phase 2 CALMA Alzheimer’s Agitation Trial
Read More →
60_GC-Pharma,-Inc.-Receives-Recognition-for-Excellence-in-Code-Clarity,-Reproducibility (1)
IGC Pharma, Inc. Receives Third Award from the NIA for Excellence in Code Clarity, Reproducibility, and Usability for Alzheimer’s Detection 
Read More →
59_IGC-Pharma-Expands-CALMA-Phase-2-Trial-to-Island-Health’s
IGC Pharma Expands CALMA Phase 2 Trial to Island Health’s Royal Jubilee Hospital in Canada 
Read More →
58_IGC-Pharma-receives-Notice-of-Allowance-for-Novel-THC
IGC Pharma receives Notice of Allowance for Novel THC Microdose-Based Treatment for Stammering, Stuttering, and Tourette’s Syndrome 
Read More →
57_IGC-Pharma-Announces-Coverage-Report-by-Ascendiant-Capital-Marketsjpg
IGC Pharma Announces Coverage Report by Ascendiant Capital Markets about the “Reports Q1 results. We believe more positive clinical data and progress in 2025 to be strong catalysts for stock. Raising P/T to $4.50.” 
Read More →
56_IGC-Pharma-Expands-CALMA-Phase-2-Trial
IGC Pharma Expands CALMA Phase 2 Trial with Site at Lynn Health Science Institute in Oklahoma City 
Read More →
55_IGC-Pharma-Reports-First-Quarter-Fiscal-2026-Financial-Results
IGC Pharma Reports First Quarter Fiscal 2026 Financial Results; Company Accelerates Phase 2 Alzheimer’s Trial
Read More →
54_IGC-Pharma-Unveils-Groundbreaking-Preclinical--in-vitro
IGC Pharma Highlights Alzheimer’s Pipeline with Encouraging Preclinical Data on IGC-M3 and Advancing Phase 2 Cannabinoid-Based IGC-AD1 
Read More →
53-IGC-Pharma-Reports-In-Vitro-Efficacy-of-Molecule-M3
IGC Pharma Reports IGC-M3’s In Vitro Efficacy Against Alzheimer’s – Targeting key Drivers of Disease Progression
Read More →
IIGC-Pharma-to-Present-Three-Posters-on-Artificial-Intelligence
IGC Pharma to Present Advanced AI Platforms for Alzheimer’s Disease at the AAIC 2025
Read More →
IGC-Pharma-Alzheimers-Jag-Rao
IGC Pharma’s Principal Scientist Dr. Jagadeesh Rao Receives Best Researcher Award at 11th Annual World Neuroscience Awards
Read More →
IGC-Pharma-Introduces-MINT-AD
IGC Pharma Introduces MINT-AD: Proprietary AI Platform to Predict Alzheimer’s Risk and Accelerate Early Detection
Read More →
IGC-Reports-Financial-Results-for-Fiscal-Year-Ended-March-31,-2025
IGC Pharma: Fiscal Year 2025 Financial and Operational Highlights – A Year of Transformative Progress in Alzheimer’s Innovation
Read More →
IGC-Pharma-Host-Fiscal-Year-June-25-2025 (1)
IGC Pharma to Host Fiscal Year-End 2025 Shareholder Update Call on June 30, 2025
Read More →
IGC-Pharma-Expands-CALMA-Trial-to-Oklahoma
IGC Pharma Expands CALMA Trial to Oklahoma, Partnering with Dr. David McCoy at Tekton Research in Yukon 
Read More →